162 related articles for article (PubMed ID: 28642147)
1. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.
Manea E; Sojo-Dorado J; Jipa RE; Benea SN; Rodríguez-Baño J; Hristea A
Clin Microbiol Infect; 2018 Feb; 24(2):180-184. PubMed ID: 28642147
[TBL] [Abstract][Full Text] [Related]
2. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Gergely Szabo B; Kadar B; Szidonia Lenart K; Dezsenyi B; Kunovszki P; Fried K; Kamotsay K; Nikolova R; Prinz G
Clin Microbiol Infect; 2016 Dec; 22(12):990-995. PubMed ID: 27599690
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
4. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
Theriot CM; Schumacher CA; Bassis CM; Seekatz AM; Young VB
Antimicrob Agents Chemother; 2015 Mar; 59(3):1596-604. PubMed ID: 25547352
[TBL] [Abstract][Full Text] [Related]
5. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections.
Brinda BJ; Pasikhova Y; Quilitz RE; Thai CM; Greene JN
J Hosp Infect; 2017 Apr; 95(4):426-432. PubMed ID: 28153556
[TBL] [Abstract][Full Text] [Related]
6. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study.
Bishop EJ; Tiruvoipati R; Metcalfe J; Marshall C; Botha J; Kelley PG
Intern Med J; 2018 Jun; 48(6):651-660. PubMed ID: 29363242
[TBL] [Abstract][Full Text] [Related]
7. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Herpers BL; Vlaminckx B; Burkhardt O; Blom H; Biemond-Moeniralam HS; Hornef M; Welte T; Kuijper EJ
Clin Infect Dis; 2009 Jun; 48(12):1732-5. PubMed ID: 19435431
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis.
Li R; Lu L; Lin Y; Wang M; Liu X
PLoS One; 2015; 10(10):e0137252. PubMed ID: 26444424
[TBL] [Abstract][Full Text] [Related]
9. [Clostridium difficile in visceral surgery].
Herzog T; Deleites C; Belyaev O; Chromik AM; Uhl W
Chirurg; 2015 Aug; 86(8):781-6. PubMed ID: 25432576
[TBL] [Abstract][Full Text] [Related]
10. Failure of tigecycline to treat severe Clostridium difficile infection.
Kopterides P; Papageorgiou C; Antoniadou A; Papadomichelakis E; Tsangaris I; Dimopoulou I; Armaganidis A
Anaesth Intensive Care; 2010 Jul; 38(4):755-8. PubMed ID: 20715744
[TBL] [Abstract][Full Text] [Related]
11. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.
Musher DM; Logan N; Bressler AM; Johnson DP; Rossignol JF
Clin Infect Dis; 2009 Feb; 48(4):e41-6. PubMed ID: 19133801
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of refractory or recurrent Clostridium difficile infection].
Kim SW
Korean J Gastroenterol; 2012 Aug; 60(2):71-8. PubMed ID: 22926117
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ
Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
[TBL] [Abstract][Full Text] [Related]
14. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
[TBL] [Abstract][Full Text] [Related]
15. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
[TBL] [Abstract][Full Text] [Related]
16. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
Di Bella S; Nisii C; Petrosillo N
Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
18. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.
Bossé D; Lemire C; Ruel J; Cantin AM; Ménard F; Valiquette L
Infection; 2013 Apr; 41(2):579-82. PubMed ID: 22996384
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?
Pepin J
Clin Infect Dis; 2008 May; 46(10):1493-8. PubMed ID: 18419481
[TBL] [Abstract][Full Text] [Related]
20. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
